Clinical Drug Investigation

, Volume 9, Issue 6, pp 324–333 | Cite as

Clinical Interest of Once-Daily Felodipine Extended-Release in Patients with Mixed and Exertional Angina

Results of a Double-Blind Crossover Study Versus Amlodipine
  • L. Corradi
  • G. Colombo
  • Elisabetta Ravera
  • A. Lotto
Original Research Clinical Use

Summary

24 patients with mixed or exertional angina pectoris were enrolled in a double-blind crossover clinical study to compare the efficacy and safety of felodipine extended-release (ER) 10mg once daily versus amlodipine 10mg once daily. Admission criteria did not restrict patient selection according to exercise endurance. The crossover treatment with two 4-week phases started after washout of all antianginal drugs except sublingual nitrates. Maximal multistage exercise tests were performed before initial administration at baseline and 23 hours after the last dose of each of the 2 study drugs. Two patients dropped out, so that efficacy could be evaluated on an intention-to-treat basis in 22 patients (15 with mixed and 7 with exertional angina). At baseline the ischaemic threshold (time to onset of ST depression 21mm) was high, with a mean of 485.3 ± 174.8 seconds (n = 22, range 180 to 840 seconds). After 4 weeks of treatment, time to test termination showed an increase with both drugs, which attained statistical significance only with felodipine ER (n = 22, + 9.03%; p<0.05). The duration of ischaemia showed a decrease that was more evident with felodipine ER (n = 17, −31.19%) than with amlodipine (n = 18, −16.70%), without attaining statistical significance in either case. The significant decrease in maximal ST depression was more evident with felodipine ER (n = 17, −27.72%; p<0.001) than with amlodipine (n = 18, −19.12%; p<0.01). Furthermore, the increase in the time to onset of angina attained statistical significance with felodipine ER (n = 7, + 34.25%; p<0.05) and not with amlodipine (n = 10, + 20.72%). The decrease in the duration of angina also attained statistical significance with felodipine ER (n = 7, −24.34%; p<0.05) and not with amlodipine (n = 10, −24.58%). Adverse reactions occurred with felodipine ER in 2 of 24 (8.3%) cases and with amlodipine in 6 of 24 (25%) cases. The most frequent adverse reaction was mild to moderate peripheral oedema that occurred only during treatment with amlodipine (16.7% cases). The possible pharmacological rationale for the better therapeutic results obtained with felodipine ER is discussed by considering both its efficacy and safety.

Keywords

Nifedipine Calcium Antagonist Amlodipine Felodipine Drug Invest 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ljung B. Vascular selectivity of felodipine. Drugs 1985; 29Suppl. 2: 46–58PubMedCrossRefGoogle Scholar
  2. 2.
    Nordlander M, Di Bona GF, Ljung B, et al. Renal and cardiovascular effects of acute and chronic administration of felodipine to SHR. Eur J Pharmacol 1985; 113: 25–36PubMedCrossRefGoogle Scholar
  3. 3.
    Emanuelsson H, Hjalmarson A, Holmberg S, et al. Effects of felodipine on systemic and coronary haemodynamics in patients with angina pectoris. Eur Heart J 1984; 5: 308–16PubMedGoogle Scholar
  4. 4.
    Emanuelsson H, Hjalmarson A, Holmberg S, et al. Effects of felodipine on pacing-induced angina pectoris. J Cardiovasc Pharmacol 1986; 8: 500–6PubMedCrossRefGoogle Scholar
  5. 5.
    Detry JMR, De Coster PM, Renkin J. Hemodynamic effects of felodipine at rest and during exertional angina pectoris. Am J Cardiol 1983; 52: 453–7PubMedCrossRefGoogle Scholar
  6. 6.
    Ardissino D, Savonitto S, Zanini P, et al. Effect of felodipine on hyperventilation induced ischemic attacks in variant angina pectoris. Am J Cardiol 1989; 63: 104–7PubMedCrossRefGoogle Scholar
  7. 7.
    Chimienti M, Negroni MS, Pusineri E, et al. Once daily felodipine in preventing ergonovine-induced myocardial ischaemia in Prinzmetars variant angina. Eur Heart J 1994; 15: 389–93PubMedGoogle Scholar
  8. 8.
    Tweddel AC, Johnsson G, Pringle TH, et al. The systemic and coronary haemodynamic effects of felodipine in patients with coronary heart disease. Eur Heart J 1983; 4: 699–705PubMedGoogle Scholar
  9. 9.
    Feldman RL, Hill JA, Conti JB. Analysis of epicardial coronary response to nifedipine alone and in combination with intracoronary nitroglycerine in patients with coronary disease. Am Heart J 1983; 105: 651–8PubMedCrossRefGoogle Scholar
  10. 10.
    Hayashi M, Aizawa Y, Satoh M, et al. Effect of nifedipine on neuropeptide Y induced coronary vasoconstriction in anesthetized dogs. Jpn Heart J 1986; 27: 251–7PubMedCrossRefGoogle Scholar
  11. 11.
    Kleinbloesem CH, Van Brummelen P, Danhof M, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987; 41: 26–30PubMedCrossRefGoogle Scholar
  12. 12.
    Culling W, Ruttley MSM, Sheridan DJ. Acute hemodynamic effects of felodipine during beta blockade in patients with coronary artery disease. Br Heart J 1984; 52: 431–4PubMedCrossRefGoogle Scholar
  13. 13.
    Emanuelsson H, Holmberg S. No adverse effects from high doses of felodipine to patients with coronary artery disease. Clin Cardiol 1985; 8: 329–36PubMedCrossRefGoogle Scholar
  14. 14.
    Sheridan JV, Thomas PA, Routledge PA, et al. Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris. Br J Clin Pharmacol 1987; 23: 391–6PubMedCrossRefGoogle Scholar
  15. 15.
    Santoro G, Savonitto S, Di Bello V, et al. Twenty-four-hour activity of felodipine extended release in chronic stable angina pectoris. Am J Cardiol 1991; 68: 457–62PubMedCrossRefGoogle Scholar
  16. 16.
    Scardi S, Pandullo C, Pivotti F, et al. Acute effects of felodipine in exertional angina pectoris. Am J Cardiol 1988; 61: 691–5PubMedCrossRefGoogle Scholar
  17. 17.
    Verdecchia P, Gatteschi C, Benemio G, et al. Increased exercise tolerance and reduced electrocardiographic ischemia 3 and 12 hours after oral felodipine in effort angina. Eur Heart J 1989; 10: 70–6PubMedGoogle Scholar
  18. 18.
    Lorimer AR, MacFarlane P, Pringle S, et al. The effects of felodipine in angina pectoris. Eur J Clin Pharmacol 1990; 38: 415–9PubMedCrossRefGoogle Scholar
  19. 19.
    Sangiorgio P, Di Pasquale G, Savonitto S, et al. Felodipine in chronic stable angina: a randomized, double-blind, placebo controlled, cross-over study. Eur Heart J 1990; 11: 1011–7PubMedGoogle Scholar
  20. 20.
    Ardissino D, Savonitto S, Mussini A, et al. Felodipine (once daily) versus nifedipine (four times daily) for Prinzmetal’s angina pectoris. Am J Cardiol 1991; 68: 1587–92PubMedCrossRefGoogle Scholar
  21. 21.
    Kinnard DR, Harris M, Hossack KF. Amlodipine in angina pectoris: effect on maximal and submaximal exercise performance. J Cardiovasc Pharmacol 1988; 12Suppl. 7: 110–3CrossRefGoogle Scholar
  22. 22.
    Taylor SH, Lee P, Jackson N, et al. A four-week double-blind, placebo controlled, parallel dose-response study of amlodipine in patients with stable exertional angina pectoris. Am Heart J 1989; 118: 1133–4PubMedCrossRefGoogle Scholar
  23. 23.
    Glasser SP, Wizda West T. Clinical safety and efficacy of once-daily amlodipine for chronic stable angina pectoris. Am Heart J 1989; 118: 1127–8PubMedCrossRefGoogle Scholar
  24. 24.
    Perondi R, Pomidossi G, Saino A. Felodipina. Nuovo calcioantagonista diidropiridico O.D. ad elevata selettivita vascolare. Profilo farmacologico e clinico. Milano: Masson, 1992: 75–6Google Scholar
  25. 25.
    Gustafsson D. Possible microvascular mechanisms involved in calcium antagonist oedema formation. Acta Physiol Scand 1985; 124Suppl. 542: 420Google Scholar
  26. 26.
    Di Bona GF. Effects of Felodipine on renal functions in animals. Drugs 1985; 29Suppl. 2: 168–5CrossRefGoogle Scholar
  27. 27.
    Edgar B, Bengisson B, Eimfeldt P, et al. Acute diuretic/natriuretic properties of felodipine in man. Drugs 1985; 29Suppl. 2: 176–84PubMedCrossRefGoogle Scholar
  28. 28.
    Leonetti G, Gradnik R, Terzoli L, et al. Effects of single and repeated doses of the calcium antagonist felodipine on blood pressure, renal function, electrolytes and water balance, and renin-angiotensin-aldosterone system in hypertensive patients. J Cardiovasc Pharmacol 1989; 8: 1243–8CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • L. Corradi
    • 1
  • G. Colombo
    • 2
  • Elisabetta Ravera
    • 3
  • A. Lotto
    • 4
  1. 1.Department of MedicineOspedale CivileBroniItaly
  2. 2.Department of CardiologyOspedale PredabissiMelegnano, MilanItaly
  3. 3.Medical DepartmentSchering-Plough SpAMilanItaly
  4. 4.Department of CardiologyOspedale MaggioreMilanItaly

Personalised recommendations